Hepatitis B Virus (HBV)

Why is this virus a problem?

The World Health Organisation estimates that 260 million people worldwide have chronic hepatitis B virus (HBV) infection, accounting for substantial morbidity and mortality. Particularly in populations where HIV infection is also endemic, there is evidence of an emerging burden of chronic liver disease. The urgent need to tackle this problem is recognised by the United Nations Sustainable Development Goals, which set out the ambitious challenge of eliminating the public health threat of HBV by the year 2030. 

Although there is a safe and effective vaccine against hepatitis B, the virus continues to be transmitted due to incomplete vaccination coverage, ongoing mother-to-child transmission, vaccine escape mutants, and failure of some individuals to mount an adequate immune response. There is a range of antiviral drugs that can be used to suppress the virus, but there come with a potential risk of drug-resistance, and even successful therapy must be taken life-long in most cases.

Although HBV affects 10-fold more people than HIV worldwide, it has been neglected by research, and by clinical and public health services, leading to poor awareness and education, stigma and discrimination, and a lack of robust data on which to base interventions. Many parts of Africa are particularly vulnerable to these problems.


Africa drug resistance cartoon

What are we doing about it?

Our research group at the University of Oxford, led by Dr Philippa Matthews, is working on diverse challenges that must be tackled if we are to meet the 2030 target. Through a variety of collaborations, we have been able to make progress in assessing some of these areas, including:

  1. Filling in gaps in our understanding of epidemiology and transmission, through careful assessment of individual clinical cohorts and a systematic analysis of pan-Africa data;
  2. Developing a better understanding of which patients are at most risk of long-term liver disease, and identifying characteristics associated with suppression or natural clearance of the virus. 
  3. Using biomarkers to better monitor disease progression or clearance;
  4. Recognising and tackling stigma associated with HBV infection, and working with patients to understand their individual experiences.
  5. Defining relevant polymorphisms in the viral genetic code that are associated with escape from drugs, vaccines or the host immune response;
  6. Assessing progress that has been made through vaccination programmes, and projecting the extent to which the 2030 target can be met, using a combination of clinical data, cost effectiveness analysis and mathematical modelling;

Our vision is to enhance advocacy for HBV, leading to better recognition, education and funding of both clinical and research infrastructure. Through understanding behaviour, providing education and striving to develop political advocacy, we hope to be able to influence better access to diagnosis and treatment.

By pursuing a robust understanding of host and viral correlates of control and clearance, we can advance patient-stratified care and ultimately help to inform the design of curative therapies.

We are strong supporters of data sharing, and ensure our work is available on pre-print servers (such as BioRxiv) ahead of peer-reviewed publication whenever possible. 

HBV word cloud


We work in partnership with other groups studying viral hepatitis based in Oxford, including Prof Ellie Barnes, Prof Jane McKeating and Prof Paul Klenerman. We have developed close links with Dr Jose Lourenco and Prof Sunetra Gupta to work on mathematical modelling of HBV infection. 

A partership with the Wellcome Trust for Human Genetics has underpinned the development of a pipeline for next generation sequencing of HBV (working with Dr David Bonsall, Dr Mariateresa deCesare, Dr Rory Bowden) and we are working with the Modernising Medical Microbiology group (led by Prof Derrick Crook) to develop diagnostic sequencing tools. 

Through working with the NIHR Health Informatics Collaborative ('HIC'), we are developing better routes to accessing 'Big Data' from routine clinical laboratories, with the long-term goal of collating anonymised data from centres across the UK to drive quality improvement and answer clinical research questions.

Our clinical cohorts in South Africa are a result of productive collaborations with clinical and research teams at the University of Stellenbosch (co-ordinated by Dr Tongai Maponga and Dr Chikezie Nwankwo) and the University of the Free State (co-ordinated by Dr Nickie Goedhals). We have recently developed links with the MRC General Population Cohort in Uganda (Prof Rob Newton and Prof Janet Seeley). 


This work is funded by a Wellcome Trust Intermediate Fellowship. I have also received research grants from the Rosetrees Trust, University of Oxford John Fell Fund, MRC Global Challenges Research Fund, and British Infection Association.

Diagnostic viral sequencing work is funded by the Oxford BRC




...for more on HBV, as well as other infections of crucial relevance to global health, my illustrated textbook was published by Oxford University Press in July 2017

Trop Med Notebook